Biocryst Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.
Did you know?
BCRX's revenue grew at a 61.8% CAGR over the last 6 years.
Current Price
$9.19
+0.33%Profile
Valuation (TTM)
Market Cap$1.93B
P/E7.33
EV—
P/B—
Shares Out210.54M
P/Sales2.21
Revenue$874.84M
EV/EBITDA6.15
Biocryst Pharmaceuticals Inc (BCRX) Stock News
BCRX Stock News & Headlines
Latest stock news and headlines for Biocryst Pharmaceuticals Inc (BCRX). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $9.19. Market cap: $1.93B. Sector: Healthcare. Industry: Biotechnology. This page aggregates the latest news articles relevant to BCRX from financial news sources, helping investors stay current on events that may impact Biocryst Pharmaceuticals Inc's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Biocryst Pharmaceuticals Inc (BCRX).